コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 es (interleukin-17A, TNF, interleukin-6, and interferon-gamma).
2 eins, which are upregulated upon exposure to interferon gamma.
3 cells that express tumor necrosis factor and interferon gamma.
4 odeling, the JAK-STAT signaling pathway, and interferon gamma.
5 wing stimulation with lipopolysaccharide and interferon gamma.
6 iated with higher baseline concentrations of interferon gamma.
7 pha, interleukin 1beta (IL-1beta), IL-6, and interferon gamma.
8 pression of IRF8 that was further induced by interferon-gamma.
9 rophages by limiting the effects of systemic interferon-gamma.
10 n of interleukin-4 and reduced production of interferon-gamma.
11 ic islets treated with interleukin-1beta and interferon-gamma.
12 o-cultures and in vivo, in part by secreting interferon-gamma.
13 y-stimulating factor and monokine induced by interferon-gamma.
14 and 1 and IL-10, and decreased expression of interferon-gamma.
15 on factor and its expression is augmented by interferon-gamma.
17 [3.1%-18.2%]; P < .05), reduced CD4+ T-cell interferon-gamma (21% [0.5%-28%]; P < .05) and granzyme
18 al epithelial cells (HCE-T cells) exposed to interferon-gamma, a cytokine elevated in SS, showed up t
21 in (IL)-2 (P = .004), but similar amounts of interferon-gamma, after stimulation with tetanus toxoid.
22 gamma receptor 1, which mediates response to interferon gamma, an essential molecule for T-cell-media
23 programmed death-1 expression and defects in interferon gamma and antigen presentation pathway compon
24 differentiation capacity and expressed less interferon gamma and interleukin 17 after polyclonal sti
25 Bs levels and cells producing HBsAg-specific interferon gamma and interleukin 2 (T-helper 1-type cyto
26 th acute infection and reduced the levels of interferon gamma and transforming growth factor beta (TG
27 reduced production of the OL toxic molecules interferon-gamma and chemokine (C-X-C motif) ligand, CXC
28 s normal skin showed increased expression of interferon-gamma and chemokines that attract T cells and
29 mory phenotype and were capable of producing interferon-gamma and destroying target cells ex vivo or
30 -1beta (IL-1beta), IL-6, IL-8, IL-10, IL-17, interferon-gamma and differential T and B cell subset ly
31 n of interleukin (IL)-12 depends strictly on interferon-gamma and is controlled negatively by IL-4 si
32 or Cxcr3 and produce both the T(H)1 cytokine interferon-gamma and the T(FH)-associated cytokine inter
33 on of a Th1-biased response characterized by interferon-gamma and tumor necrosis factor-alpha cytokin
35 cells was assessed by release of cytokines (interferon-gamma and tumor necrosis factor-alpha), upreg
36 g CEnCs against effector T cell-mediated and interferon-gamma and tumor necrosis factor-alpha-induced
38 ]-21, IL-1beta, tumor necrosis factor-alpha, interferon-gamma) and CCR5, HLA-DR, CD38, and Th17 frequ
39 of antigen-specific T-helper 1 (IL-2, IL-12, interferon-gamma) and T-helper 2 (IL-4, IL-5) cytokines
40 d decreased cytokine (ie, interleukin 1beta, interferon gamma, and interleukin 17) responses when med
41 o production of tumor necrosis factor alpha, interferon gamma, and interleukin 1beta but increased ph
42 significantly elevated levels of eotaxin-1, interferon-gamma, and IL-12p70 relative to children with
44 antigen-specific B-cell, and interleukin 2-, interferon gamma-, and tumor necrosis factor alpha-secre
45 icacy and safety of emapalumab (a human anti-interferon-gamma antibody), administered with dexamethas
46 vere disease) and 16 unexposed donors, using interferon-gamma-based assays with peptides spanning SAR
47 Infusion of maternal VSTs, isolated using interferon-gamma capture, associated with clinical impro
51 increased motility, and higher production of interferon gamma, compared with T cells from unirradiate
52 s infection causes intestinal pathology, and interferon-gamma controls early infection while T cells
53 yte-macrophage colony-stimulating factor and interferon-gamma) critical to the cytokine storm that am
55 hils were essential for the activation of an interferon-gamma-dependent pathway of immune resistance,
57 lular and humoral responses were measured by interferon-gamma ELISPOT and virus neutralization assay
58 after transplantation was assessed using an interferon gamma enzyme-linked immunosorbent spot assay.
61 D11c(+) macrophage) M1-like polarization and interferon-gamma-expressing T-helper type 1 (Th1) cells
62 afin improved leptin sensitivity via reduced interferon-gamma expression and induced adipose leptin e
64 hrough the rapid synthesis of a glycosylated interferon-gamma fragment and the chemokine-binding prot
67 ccinated infants had increased production of interferon gamma (IFN-gamma) and monokine induced by gam
69 the absence of miR-155, there was decreased interferon gamma (IFN-gamma) and tumor necrosis factor a
71 nters underwent ELISPOT testing to enumerate interferon gamma (IFN-gamma) binding spot-forming units
72 higher levels of interleukin-12 (IL-12) and interferon gamma (IFN-gamma) by as early as 4 hpi, but t
77 and evaluated CAR-T cell activation through interferon gamma (IFN-gamma) production and CD107a membr
78 g superantigen-induced T cell activation and interferon gamma (IFN-gamma) production during infection
79 ity (CMV-CMI) can be determined by levels of interferon gamma (IFN-gamma) production using an enzyme-
81 at influenza diagnosis and 28 days later for interferon gamma (IFN-gamma), IL-4, IL-13, and IL-10.
82 Furthermore, we quantified the number of interferon gamma (IFN-gamma)-producing CD4 T cells speci
83 Adhesin domain immunization also elicited interferon gamma (IFN-gamma)-producing CD8-positive (CD8
84 ound that early intratumoral accumulation of interferon gamma (IFN-gamma)-producing natural killer (N
87 h reduced liver MDSC accumulation, increased interferon-gamma (IFN-gamma) and granzyme B production i
90 vels of interleukin (IL)-1beta, IL-6, IL-17, interferon-gamma (IFN-gamma) and superoxide dismutase 1
91 -22), whereas ILC1s produced proinflammatory interferon-gamma (IFN-gamma) and tumor necrosis factor-a
95 was needed to prevent premature induction of interferon-gamma (IFN-gamma) expression in T cells and t
97 In contrast to the importance of type II interferon-gamma (IFN-gamma) in control of toxoplasmosis
99 In this work, we designed a conjugated anti-interferon-gamma (IFN-gamma) molecular aptamer beacon (M
101 decreases interleukin (IL)-12/IL-18-induced interferon-gamma (IFN-gamma) production versus controls.
106 specific T cells expressed higher amounts of interferon-gamma (IFN-gamma) receptor and were more susc
107 study of long-term T-cell responses using an interferon-gamma (IFN-gamma) release assay and a flow cy
108 dentified using the tuberculin skin test and interferon-gamma (IFN-gamma) release assay IGRA, and a p
109 el vaccines against tuberculosis (TB) and in interferon-gamma (IFN-gamma) release assays (IGRAs).
110 and death receptor ligand TRAIL, as well as interferon-gamma (IFN-gamma) secretion, was more pronoun
111 d from WNV or ZIKV infection, T cell-derived interferon-gamma (IFN-gamma) signaling in microglia unde
113 actor Elf5 in TNBC cells activates intrinsic interferon-gamma (IFN-gamma) signalling, promoting tumou
114 cebo in the median fold increase in secreted interferon-gamma (IFN-gamma) was 38.2-fold (95% CI, 4.7-
115 ference was observed regarding the number of interferon-gamma (IFN-gamma)+ cells in lesions from preg
116 A polymerase II pause release in response to interferon-gamma (IFN-gamma), a universal cytokine invol
117 -alpha), interleukin-6 (IL-6), IL-1beta, and interferon-gamma (IFN-gamma), as well as reduces cell ap
118 d with a significant increase in gB-elicited interferon-gamma (IFN-gamma), granzyme B, and CD107a and
119 t study evaluated the in vitro production of interferon-gamma (IFN-gamma), interleukin (IL)-6, and IL
120 that increased expression of factors such as interferon-gamma (IFN-gamma), vascular endothelial growt
121 ulin G1 monoclonal antibody directed against interferon-gamma (IFN-gamma), which in November 2018 rec
122 onstrate that Ct growth inhibition occurs by interferon-gamma (IFN-gamma)-mediated depletion of intra
126 ation, we find inflammatory cytokines (e.g., interferon gamma [IFN-gamma] and tumor necrosis factor a
127 med macrophage polarization by suppressing M(interferon-gamma [IFN-gamma]) yet promoting M(interleuki
128 major resident retinal cell types respond to interferon gamma (IFNG) by changing their patterns of ge
132 nockdown of FTO sensitizes melanoma cells to interferon gamma (IFNgamma) and sensitizes melanoma to a
133 is vital, inflammatory cytokines, including interferon gamma (IFNgamma) and TNFalpha, also facilitat
136 nes involved in antigen presentation and the interferon gamma (IFNgamma) pathway play an important ro
139 ns (P < 0.01) were observed between elevated interferon gamma (IFNgamma)-expressing T cytotoxic LPLs
140 ture of the establishment and maintenance of interferon gamma (IFNgamma)-induced priming of human cel
142 We also demonstrate a role for the cytokine interferon-gamma (IFNgamma) and the enzyme transglutamin
144 led to a reduction in interleukin (IL)-4 and interferon-gamma (IFNgamma) in the diencephalon, as well
147 d by high levels of infiltrating T cells and interferon-gamma (IFNgamma) signalling, improves the res
150 increases in CSF white blood cells, protein, interferon-gamma (IFNgamma), interleukin (IL)-6, IL-10,
151 reduced secretion of interleukin-2 (IL2) and interferon-gamma (IFNgamma), two factors critical for T
152 cells suppressed CD8(+) T cell secretion of interferon-gamma (IFNgamma), which would otherwise block
155 ased STAT activation in vitro in response to interferon-gamma, IL-2 and IL-4 that is reverted by the
158 ction of higher (p < 0.01) concentrations of interferon-gamma in plasma of low responders compared to
160 22 convert into ILC1-like cells that produce interferon-gamma in vitro, but whether this conversion o
164 a, monocyte chemoattractant protein (MCP)-1, interferon gamma-induced protein (IP)-10, monokine induc
165 L-2Ralpha), sCD27, B-cell activating factor, interferon gamma-induced protein 10 (IP-10), soluble int
166 very high CSF levels of the pro-inflammatory interferon gamma-induced protein 10 (IP-10/CXCL10) in HI
167 L)-6, IL-8, tumor necrosis factor alpha, and interferon gamma-induced protein 10 were measured under
168 , interleukin-10, interleukin-15, eotaxin-3, interferon gamma-induced protein 10, macrophage-derived
169 -1beta]/C-C motif chemokine ligand 4 [CCL4], interferon gamma-induced protein-10 [IP-10]/C-X-C motif
171 (GM-CSF) (6.6-fold), RANTES (14.8-fold), and interferon gamma inducible protein 10 kDa (IP-10) (53-fo
172 entified polymorphisms in inflammasome genes interferon gamma inducible protein 16 (IFI16) and absent
173 s associated with HIV acquisition, including interferon-gamma inducible protein (IP)-10, macrophage i
174 -reactive protein (CRP), interleukin (IL)-6, interferon-gamma inducible protein (IP)-10, soluble CD14
176 and HIN domain family member (PYHIN) protein interferon-gamma-inducible protein 16 (IFI16) detect DNA
177 responses, especially T-cell cytokines (ie, interferon gamma, interleukin 17, and interleukin 22).
179 00 cells/muL had higher median CSF levels of interferon-gamma, interleukin (IL)-6, IL-8, and IL-13, a
180 nd neutralizing) and CD4+ T-cell (expressing interferon-gamma, interleukin-2, and CD40 ligand) respon
181 osporin A (CSA), corticosteroids, dupilumab, interferon-gamma, intravenous immunoglobulins (IVIG), me
183 opeptidome response to CDK4/6 inhibition and interferon-gamma - known modulators of antigen presentat
184 unced disease, and correlates with increased interferon-gamma levels in the lungs and spleens before
190 partments and polarize naive T cells into an interferon-gamma(low), interleukin-4(high) and FoxP3(+)
192 We demonstrate that DUX4 expression blocks interferon-gamma-mediated induction of MHC class I, impl
193 malignancies, wild-type, Tax(+), and Tax(+)/interferon-gamma(-/-) mice were assessed using necropsy,
194 ir wild-type littermates and lower levels of interferon-gamma mRNA were detected in the infected muco
195 elated with soluble inflammatory biomarkers (interferon-gamma, myeloperoxidase, tumor necrosis factor
197 -derived T cells, and can be counteracted by interferon-gamma or checkpoint blockade, respectively.
199 r levels of IL-6 (P = .02), IL-10 (P = .02), interferon-gamma (P = .003), TNF-alpha (P = .006), IL-1b
201 AK-STAT, immune deficiency and cross-species interferon-gamma pathways, have advanced our understandi
202 ) T cell and CD68(+) macrophages), cytokine (interferon gamma-positive [IFN-gamma(+)] and tumor necro
203 8 [5%, 1.9-10.7]) and T-cell responses (CD4+ interferon gamma-positive and/or CD4+ interleukin 2-posi
204 otection was associated with a strong CD8(+) interferon gamma-positive recall response against NS4.
205 reduced in smokers compared with nonsmokers (interferon-gamma-positive rate, 14.9% versus 28.7%; P <
208 t increased the number of interleukin 4- and interferon gamma-producing natural killer T cells in the
209 inally identified as a receptor expressed on interferon-gamma-producing CD4(+) and CD8(+) T cells.
210 s and a modest reduction in the frequency of interferon-gamma-producing CD4(+) and CD8(+) T cells.
211 faeces that is capable of robustly inducing interferon-gamma-producing CD8 T cells in the intestine.
213 with a reduction of CD11c cells, CD4 TN, and interferon-gamma-producing EBV-specific CD4 T cells, sug
214 he transcription factor TCF1, which promotes interferon-gamma-producing gammadelta T cells (Tgammadel
216 panied by the expansion of gluten-sensitive, interferon-gamma-producing Vdelta1(+) IELs bearing T cel
217 ysis and intracellular cytokine staining for interferon gamma production at the single-peptide level.
219 reserved HSPC-NK killing, proliferation, and interferon gamma production capacity, whereas AZA dimini
220 phenotype profile associated with decreased interferon gamma production seems similar to those of ot
221 CCR5 expression), and decreased capacity of interferon gamma production were observed; mean perforin
222 ML), which displayed significantly increased interferon gamma production, degranulation, and specific
224 accompanied by profound local suppression of interferon-gamma production and cytotoxic function of lu
226 NY-eso-1-SLL-specific T-cell clone provoked interferon-gamma production and/or cytolysis upon stimul
228 pinal cord injury infected mice and enhanced interferon-gamma production by natural killer T cells as
230 the compounds to stimulate proliferation and interferon-gamma production of Vgamma9Vdelta2 T cells.
231 ence (CMV-CD8+), as measured by enumeration, interferon-gamma production, and CD107a/b degranulation.
232 e, spike, and nucleocapsid peptides elicited interferon-gamma production, in 27 (59%), 12 (26%), and
234 KO-CAR-T cells with strong activation (CD25, interferon gamma), proliferation, and specific killing u
235 tumor demonstrated a frameshift deletion in interferon gamma receptor 1, which mediates response to
236 colitis and lethal hemorrhagic pneumonia in interferon gamma receptor-deficient (IFNgammaR(-/-)) mic
238 mice lacking the pro-inflammatory caspase 1, interferon gamma-receptor, and nitric oxide synthase (Ca
239 associated with upregulation of T cell- and interferon-gamma-related gene expression, but downregula
241 .Methods People with a positive skin test or interferon gamma release assay (IGRA) result from 1985 t
242 TBI) testing (tuberculin skin test [TST] and interferon gamma release assay [IGRA]), and human immuno
243 computed tomography [CT calcification], and interferon gamma release assay for tuberculosis [TB-IGRA
244 of tuberculosis infection, as assessed by an interferon gamma release assay in the fourth year, among
246 Plus (QFT-Plus) is the latest generation of interferon gamma release assays (IGRAs) to receive appro
249 umbers of individuals who could be tested by interferon-gamma release assay (IGRA) and treated for LT
250 with smear-positive tuberculosis (TB) had an interferon-gamma release assay (IGRA) at baseline and 14
251 usehold contacts of TB cases were tested for interferon-gamma release assay (IGRA) conversion between
252 investigated feasibility and accuracy of an interferon-gamma release assay (IGRA) for detection of T
254 ecific cell-mediated immunity (CMI) using an interferon-gamma release assay to predict CMV infection
255 ed TB screening (tuberculin skin test and/or interferon-gamma release assay) was performed in 15 pati
256 ed TB screening (tuberculin skin test and/or interferon-gamma release assay) was performed in 15 pati
257 is infection (defined by positive results on interferon-gamma release assay) without evidence of acti
258 M. tuberculosis sensitization determined by interferon-gamma release assay, 12/23 participants had n
259 tly negative tuberculin skin tests (TST) and interferon-gamma release assays (IGRA), after close cont
264 titers and median frequencies of F-specific interferon gamma-secreting T cells also increased substa
268 antibodies were detected, but cross-reactive interferon-gamma-secreting T cells were detected in the
270 ddition, low responder pigs with high plasma interferon-gamma showed lower (p < 0.01) birth weights t
271 by polarization with lipopolysaccharide and interferon-gamma, showed significantly higher expression
272 d a positive-feedback loop between PPARD and interferon gamma signaling that sustained gastric inflam
274 nd highlighted the importance of cancer cell interferon-gamma signaling in modulating NK activity.
275 (e.g. the Cadherin pathway for COPD and the interferon-gamma signaling pathway for breast cancer) as
276 higher levels of interleukin (IL) 6, IL-10, interferon-gamma, soluble tumor necrosis factor-related
278 12 induced sustained intratumoural levels of interferon-gamma, substantially reduced its systemic lev
280 ecretion of pathogenic cytokines (eg, IL-17, interferon-gamma, tissue necrosis factor, granulocyte-ma
282 roinflammatory T helper 1-type features with interferon-gamma, TNFalpha, and TNFR1 expression, loss o
283 osition of proteasome catalytic subunits via interferon-gamma treatment or siRNA knockdown results in
285 Supplementation of antifungal agents with interferon-gamma treatment slowed disease progression, a
286 easured CSF concentrations of the following: interferon gamma, tumor necrosis factor (TNF) alpha, gra
287 significant increases in interleukin 1beta, interferon gamma, tumor necrosis factor alpha, and ioniz
288 th the increased production of the cytokines interferon gamma, tumor necrosis factor alpha, interleuk
289 y subjects, and that NK cells expressed more interferon-gamma, tumor necrosis factor (TNF), granzyme
290 using intracellular cytokine (interleukin-2, interferon-gamma, tumor necrosis factor-alpha) staining
296 m levels of tumor necrosis factor -alpha and interferon-gamma were significantly increased in the CSD
297 (tumor necrosis factor-alpha) and IFN-gamma (interferon-gamma) were upregulated in the DC ACT renal C
298 Activated mutant SOD1 CD8(+) T cells produce interferon-gamma, which elicits the expression of the MH
299 CD4 tissue-resident memory T cells secrete interferon-gamma, which induces expression of chemokines
300 lls were significantly more prone to produce interferon-gamma, while secretion of the cytotoxicity mo